JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

Tech entrepreneur and Tesla (TSLA, Financials) CEO Elon Musk's disclosure of using weight-loss pharmaceuticalsincluding Eli Lilly's (LLY, Financials) Mounjaro and Novo Nordisk's Ozempichas drawn ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Shelby Knowles / Bloomberg via Getty Images Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive ...

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...

The bottom line: We're maintaining our $580 fair value estimate for Eli Lilly, and the firm's tirzepatide molecule (diabetes drug Mounjaro and obesity/sleep apnea drug Zepbound) and ...